Dr Mymoona Alzouebi
Consultant Clinical Oncologist
MBChB, MRCP, DTMH, MSc Oncology, FRCR
Practices at: BMI Thornbury Hospital
She is an expert in cancer care using the most advanced and up to date treatment modalities.
She is actively involved in clinical trials and research and is the local principal investigator on several national clinical trials.
Dr Alzouebi holds a substantive NHS post as a Consultant Clinical Oncologist, Weston Park Hospital; Sheffield Teaching Hospital NHS Foundation Trust.
Dr Alzouebi qualified from the University of Sheffield in 2004. She undertook general medical training in the Yorkshire Deanery and achieved MRCP and DTMH qualifications.
She completed the Clinical Oncology Training Programme at Weston Park Hospital in Sheffield. She obtained a Distinction in a Master’s Degree in Oncology from the University of Nottingham and her dissertation research was published in a peer reviewed journal.
She successfully obtained Fellow of Royal College of Radiologist (Clinical Oncology) qualification in 2012.
- Systemic Drug therapy/Chemotherapy: Novel Targeted Anticancer Drug Treatment; Systemic Chemotherapy; Immunotherapy; Monoclonal Antibodies; Endocrine therapy; Radium-223; Tyrosine Kinase therapy
- Radiotherapy; Intensity Modulated Radiotherapy (IMRT); Image Guided Radiotherapy (IGRT), Adaptive Radiotherapy Stereotactic Ablative Radiotherapy; SABR
- In partnership with Genesiscare; SpaceOAR for prostate radiotherapy
- Areas of interest
- Advanced radiotherapy techniques for prostate and bladder cancer
- Prostate SABR
- Chemotherapy in prostate, kidney and bladder cancer
•M Alzouebi, R Jones. Outcomes of 10 years prescribing practice for first line metastatic kidney cancer. NCRI 2018
•M Alzouebi, JR Goepel, JM Horsman and BW Hancock. Primary thyroid lymphoma: The 40-year experience of a UK lymphoma treatment centre. Int J Oncol 40: 2075-2080, 2012
•M Alzouebi, S Pledge and J Martin. Are outcomes of adjuvant vaginal vault brachytherapy in endometrial cancer related to the way it is delivered? Journal of Radiotherapy in Practice. FirstView Article : pp 1-14 Published online: 12 December 2011
•M Alzouebi, P Fisher, PJ Woll, MQ Hatton, BH Foran. Audit of adjuvant vinorelbine and cisplatin for patients with resected NSCLC. Lung Cancer 2010;67:S1
•M Alzouebi, P Sarrigiannis, M Hadjivassiolou. Acute Polyradiculopathy with renal failure; mind the anion gap – Journal of Neurology, Neurophysiology and Psychiatry Psychiatry 2008;79:842-844
•M Alzouebi. Paediatric Chest Radiographs. StudentBMJ 2005; 13:309-352
•M Alzouebi, M McAlindon, DS Sanders. Patients starving before percutaneous endoscopic gastrostomy (PEG) placement may be at risk of refeeding syndrome. BAPEN 2004; 63 (1)
- General Medical Council
- Royal College of Radiologists
- British Uro-Oncology Group
Radiotherapy; Chemotherapy; Biological Treatment, Novel Targeted Anticancer Drug Treatment; Intensity Modulated Radiotherapy (IMRT); Prostate Cancer; Bladder Cancer; Kidney Cancer; IMRT, IGRT, Adaptive Radiotherapy; Systemic Chemotherapy; Immunotherapy; Monoclonal Antibodies; Biological Therapy; Endocrine Oncology; Urological Cancers; Stereotactic Ablative Radiotherapy; SABR; Radium-223.
Current NHS and /or University Posts
Consultant in Clinical Oncology in Urological Malignancies at Weston Park Cancer Centre, Sheffield
M Alzouebi, R Jones. Outcomes of 10 years prescribing practice for first line metastatic kidney cancer. NCRI 2018.
M Alzouebi, JR Goepel, JM Horsman and BW Hancock. Primary
Ways to pay
Pay for yourself
Pay for yourself with our fixed price packages. This includes your pre-assessment, treatment, follow-ups and six months of aftercare.
Pay with health insurance
We are widely recognised by health insurers. Ask your insurer about your cover and for an insurer pre-authorisation code.
Spread the cost
Pay for yourself with monthly repayments spread over 12 months, interest-free (terms and conditions apply)